Cryptococcosis is a serious infectious disease in the immunocompromised patient. It is reported to be the fourth most common infectious complication of AIDS. The capsule is the most important virulence factor produced by Cryptococcus neoformans, the etiologic agent of cryptococcosis. It is the interface between the yeast and its environment. One of the most important biological activities of the cryptococcal capsule is the ability to activate the alternative complement pathway, leading to deposition of opsonic fragments of C3 into and onto the capsule. Opsonization in this manner is essential for phagocytosis of the yeast by macrophages and neutrophils. Studies during the current grant period found that the cryptococcal capsule may be the most powerful activator of the alternative pathway described to date. Indeed, it appears to be the only microbial capsule with an intrinsic ability to focus alternative pathway activation. Understanding the unique complement activating properties of the cryptococcal capsule is fundamental to understanding opsonization of the yeast and the complement depletion that occurs during cryptococcal sepsis. This latter point is of particular concern as patients with AIDS continue to develop overwhelming cryptococcemia. The overall hypothesis for this proposal is that the complement activating properties of the cryptococcal capsule are a function of one or more structural components of the capsular polysaccharide that influence initiation, amplification and regulation of the alternative pathway. This question will be approached by examination of the influence of specific molecular characteristics of the capsule on individual components of the alternative pathway. The study will pursue five specific aims: 1.) identify the component of the cryptococcal capsule that mediates initiation of the alternative pathway; 2.) determine the molecular binding site for activated C3b; 3.) identify the mechanisms by which the cryptococcal capsule regulates amplification of the alternative pathway; 4.) identify the mechanisms for regulation of decay of C3b to iC3b by the cryptococcal capsule; and 5.) determine if activation of the complement system in vivo follows the paradigms that have been established for activation in vitro. Successful pursuit of these aims will provide an understanding, at a molecular level, of one of the most important and intriguing biological activities of the cryptococcal capsule. Moreover, it will provide information regarding regulation of the complement system by a medically important microorganism.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI014209-19
Application #
2003172
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Project Start
1977-07-01
Project End
1999-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
19
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Nevada Reno
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
146515460
City
Reno
State
NV
Country
United States
Zip Code
89557
Ezeanolue, Echezona E; Nwizu, Chidi; Greene, Gregory S et al. (2016) Brief Report: Geographical Variation in Prevalence of Cryptococcal Antigenemia Among HIV-Infected, Treatment-Naive Patients in Nigeria: A Multicenter Cross-Sectional Study. J Acquir Immune Defic Syndr 73:117-21
Kozel, Thomas R; Wickes, Brian (2014) Fungal diagnostics. Cold Spring Harb Perspect Med 4:a019299
Gates-Hollingsworth, Marcellene A; Kozel, Thomas R (2013) Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen. Clin Vaccine Immunol 20:634-5
Kozel, Thomas R; Bauman, Sean K (2012) CrAg lateral flow assay for cryptococcosis. Expert Opin Med Diagn 6:245-51
Percival, Ann; Thorkildson, Peter; Kozel, Thomas R (2011) Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen. Clin Vaccine Immunol 18:1292-6
Jarvis, Joseph N; Percival, Ann; Bauman, Sean et al. (2011) Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 53:1019-23
Boxx, Gayle M; Kozel, Thomas R; Nishiya, Casey T et al. (2010) Influence of mannan and glucan on complement activation and C3 binding by Candida albicans. Infect Immun 78:1250-9
Pericolini, Eva; Gabrielli, Elena; Cenci, Elio et al. (2009) Involvement of glycoreceptors in galactoxylomannan-induced T cell death. J Immunol 182:6003-10
Gates-Hollingsworth, Marcellene A; Kozel, Thomas R (2009) Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule. Mol Microbiol 74:126-38
Gabrielli, Elena; Pericolini, Eva; Cenci, Elio et al. (2009) Antibody complementarity-determining regions (CDRs): a bridge between adaptive and innate immunity. PLoS One 4:e8187

Showing the most recent 10 out of 75 publications